louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00660608: Conservation of Red Cell Mass , Oxygen Supply and Demand in Cardiac Surgery
Official title: Conservation of Red Cell Mass, Oxygen Supply and Demand in Cardiac Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Transfusion regulation
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
Collaborators: name: Daxor Corporation
First posted: 2008-04-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pre-OP, surgery clinics, inpatients

Brief summary: Fifty patients will be enrolled into the study. The purpose of the study is to investigate the relevance of Hct levels in determining need for transfusion during operations employing bypass as well as to test the hypothesis that, while HCt levels may decrease during surgery , red blood cell mass and tissue oxygenation remain fairly constant.

Detailed description: Fifty adults( male or female-nonpregnant) whose weight is between 55-85 kg and are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass for CABG or primary valve repair or replacement will be eligible. Patients with any history of abnormal bleeding disorders, urgent or emergent need for surgery, and combination surgeries will be excluded. Blood volume analysis will be performed with the DAXOR Blood Volume Analyzer BVA-100 System and the Volumex HSA I-131 radiopharmaceutical for use for determining circulating volume. Multiple timed sample points will be obtained. The DAXOR blood volume analyzer will batch samples and with input of patients height, weight, gender, time of draw, and corresponding Hct, calculate circulating total blood volume. We hypothesize that Total red cell mass is relatively well conserved( \<20% decrease) during and immediately after surgery as long as major bleeding does not occur. We hypothesize that decrease in Hct during surgery are related to changes in circulating plasma volume. Total red cell O2 carrying capacity and O2 economics will be measured and it is also hypothesized that lowered Hct values, even as low as 15%, do not independently signal a tissue or whole body O2 deficit.

Eligibility criteria: Inclusion Criteria:

* Patient scheduled to undergo elective Cabg or primary repair/replacement on bypass pump.
* Age 18 yrs or older
* Male or non pregnant female
* Weight between 55-85 kg.

Exclusion Criteria:

* Any known bleeding risks;
* Urgent or emergent surgery;
* Combined aortic and major vascular surgery;
* Pregnant women
* If participating in another study within last 90 days.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Richmond,
country: United States
facility: VCU Medical Center
state: Virginia
Study officials:
affiliation: VCU Medical Center
name: Mark Nelson, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: VCU Medical Center
name: Carlos Arancibia, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04966208: Gingival Recession Treatment Using Two Different Surgical Techniques
Official title: Root Coverage Using Tunneling Technique of Xenogenic Collagen Matrix vs. Autologous Connective Tissue as a Treatment of Miller Class Two Gingival Recession (RCT Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gingival Recession
Root Planing
Keywords: root coverage
mucoderm
connective tissue
grafts
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-07-19
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Coronally the advanced flap is considered a predictable treatment of gingival recession but in certain situations, it needs a filler like subperiosteal connective tissue graft (CTG) which is considered as the gold standard treatment approach.

This randomized controlled trial compares the clinical benefits and effectiveness of a xenogenic collagen matrix (mucoderm, botiss, dental, Berlin, Germany) as a filler to the subperiosteal connective tissue graft (CTG).


Eligibility criteria: Inclusion Criteria:

* -The selected patients for this study are non-smokers, aged 18-60 years with multiple gingival recession (Miller class 1, or 2.) for more than two adjacent affected teeth with plaque score less than 25%

Exclusion Criteria:

* -Patients with systemic complications, psychological problems, parafunctional habits, or patients presented with Mal-posed teeth, hypermobile teeth, teeth with Miller class 3 gingival recession were excluded from this study.

Primary outcomes:
measure: The zone of keratinized gingiva
timeFrame: 6 months after the surgery
Secondary outcomes:
measure: Periodontal probing depth
timeFrame: 6 months after the surgery
measure: Clinical attachment loss
timeFrame: 6 months after the surgery
measure: Gingival recession
timeFrame: 6 months after the surgery
measure: Patient satisfaction of the esthetics
timeFrame: 6 months
Other outcomes:
Locations:
city: Assuit
country: Egypt
facility: Assiut University
Study officials:
References:
Clinical trial NCT06550908: Training Physicians to Differentiate the Paris Classification Using Artificial Colon Polyp Images
Official title: Training Physicians to Differentiate the Paris Classification Using Artificial Colon Polyp Images
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Colonic Polyp
Colon Adenoma
Keywords: Colonoscopy
Lead sponsor: Wuerzburg University Hospital
Sponsor class: OTHER
First posted: 2024-08-13
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Training in endoscopy is essential for the early detection of precursors of colorectal cancer. Up to now, this training has been carried out with image collections of findings and in practice when working on patients. We want to use artificial intelligence (AI) to better train doctors to recognise these precursors. By using generative AI, we were able to create realistic images that comply with data protection regulations and whose content can be predefined. Parts of the image can also be regenerated so that it is possible to create different precancerous stages in the same place in the image.

In this study we want to train physicians using real images or artificial images in order to compare which version helps classify polyps better.


Eligibility criteria: Inclusion Criteria:

* Physicians with or without experience in colonoscopy

Primary outcomes:
measure: Accuracy for Paris classification
timeFrame: 9 months
Secondary outcomes:
measure: Range of misclassifications for Paris classification
timeFrame: 9 months
measure: Influence of endoscopy experience on accuracy for correct Paris classification
timeFrame: 9 months
measure: Influence of time to complete course on accuracy for correct Paris classification
timeFrame: 9 months
measure: Influence regular usage of Paris classification on accuracy for correct Paris classification
timeFrame: 9 months
Other outcomes:
Locations:
Study officials:
affiliation: Wuerzburg University Hospital
name: Alexander Hann
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01828008: Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lymphomas
Keywords: Mabthera
cytokine induced killer cell
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2013-04-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: the patients with CD20-positive Lymphomas

Brief summary: To study the safety and efficacy of CD20 antibody usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Detailed description: Autologous CIK transfusion within 3 days post CD20 antibody treatment.

Eligibility criteria: Inclusion Criteria:

- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy

Exclusion Criteria:

- to refuse the therapy and need not tolerate the therapy

Primary outcomes:
measure: disease free survival
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02808208: Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
Official title: A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: End Stage Renal Disease (ESRD)
Vascular Access Complication
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2016-06-21
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this phase 1 study is to determine the role of autologous adipose derived mesenchymal stem cells in the reduction of hemodialysis arteriovenous fistula failure when applied during the time of surgical creation.


Eligibility criteria: Inclusion Criteria

* Patient between 18 and 85 years old
* Patient currently on hemodialysis or pre-dialysis and planned creation of an upper extremity AV fistula with suitable anatomy
* Ability to communicate meaningfully with investigative staff, competence to give written informed consent, and ability to comply with entire study procedures
* Life expectancy of at least 24 months

Exclusion Criteria

* Malignancy or treatment for malignancy within the previous 6 months
* Immunodeficiency including AIDS / HIV or Active autoimmune disease
* Documented hypercoagulable state or history of 2 or more DVTs or other spontaneous intravascular thrombotic events
* Pregnancy or breast feeding
* Treatment with any investigational drug/ device within 60 days prior to study entry or Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs and the AVF
* Employees of the sponsor or patients who are employees or relatives of the investigator
* History of failed organ transplant on immunosuppression

Primary outcomes:
measure: Hemodialysis outflow vein diameter
timeFrame: Baseline to 12 months after AVF creation
Secondary outcomes:
measure: Hemodialysis AVF Blood flow
timeFrame: Baseline to 12 months after AVF creation
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Sanjay Misra, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Piryani AK, Kilari S, Takahashi E, DeMartino RR, Mandrekar J, Dietz AB, Misra S. Rationale and Trial Design of MesEnchymal Stem Cell Trial in Preventing Venous Stenosis of Hemodialysis Vascular Access Arteriovenous Fistula (MEST AVF Trial). Kidney360. 2021 Sep 28;2(12):1945-1952. doi: 10.34067/KID.0005182021. eCollection 2021 Dec 30.
Clinical trial NCT04257708: Cavity Evaluation Before Intracytoplasmic Sperm Injection
Official title: Cavity Evaluation Before Intracytoplasmic Sperm Injection in Women With Infertility
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infertility
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
First posted: 2020-02-06
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with infertility

Brief summary: Uterine cavity evaluation is an integral part of assessment Of women for ICSI

Detailed description: Transvaginal us is the main role in this aspect

Eligibility criteria: Inclusion Criteria:

* women with infertility more than one year

Exclusion Criteria:

* 2omen with medical disorders

Primary outcomes:
measure: The number of women who will has positive pregnancy test
timeFrame: within a year
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Algazeerah
Study officials:
affiliation: Algezeera
name: Mahmoud Alalfy, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06903208: RFA for Superficial Lipomas
Official title: Radiofrequency Ablation As a Scar-free, Non-operative Approach to Treatment of Superficial Lipomas
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Lipoma
Keywords: lipoma
ablation
fatty tissue
fatty tumor
scarring
minimally invasive
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2025-03-30
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Lipomas are non-cancerous growths of fatty tissue that develop under the skin in approximately 1 in 1000 people, though this number may be higher. While rarely symptomatic, they often cause emotional distress due to the unappealing appearance of the mass. Treatment of unsightly lipomas is excision with local anesthetic in the office or with sedation in the operating room. The recovery period is short and the procedure is low risk; however, the result of the operation is a visible scar over the site of the lipoma. Many patients defer surgical excision because excision of a lipoma is a cosmetic procedure, but the aesthetic outcome is undesirable.

Radiofrequency ablation (RFA) is a technique that applies heat generated by a high frequency, alternating current to soft tissue. The hyperthermia produced by the current causes tissue necrosis that ablates the tissue into which the energy is directed. RFA has been successfully applied to thyroid nodules, pancreatic lesions, esophageal dysplasia and liver tumors. However, the manufacturers of the RFA technology have been focused on its application in pre-malignant and malignant lesions and have not yet considered its application to benign tumors. This study will test the success of RFA for superficial lipomas as a non-surgical option for treatment.


Eligibility criteria: Inclusion Criteria:

* Patients \>18 years old
* Patients with a lipoma \<5 cm, above the fascia on the trunk, abdomen or extremities

Exclusion Criteria:

* Lipomas of the face or neck
* Angiolipomas (identified on exam as a firm, mobile, occasionally discolored mass)
* Patients with history of hereditary retinoblastoma, Li-Fraumeni syndrome, familial adenomatous polyposis, neurofibromatosis, tuberous sclerosis and Werner syndrome
* A history of exposure to herbicides, arsenic and dioxin
* A history of radiation treatment for other cancers

Primary outcomes:
measure: Patient Satisfaction
timeFrame: 1 month, 6 months and 12 months post-procedure
measure: Change in Lesion Volume
timeFrame: Baseline, 1 month, 6 months and 12 months post-procedure
Secondary outcomes:
measure: Complication rate
timeFrame: 1 month, 6 months and 12 months post-procedure
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Katherine Fischkoff, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06865508: Photo Biomodulation Therapy for Alveolar Osteitis Recovery in Oral Contraceptive Users
Official title: Photo Biomodulation Therapy for Alveolar Osteitis Recovery in Oral Contraceptive Users
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alveolar Osteitis
Keywords: alveolar osteitis and oral contraceptive
Lead sponsor: Badr University
Sponsor class: OTHER
First posted: 2025-03-10
Enrollment: 50
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study is a randomized clinical trial (RCT) designed to evaluate the effectiveness of laser therapy combined with zinc oxide eugenol dressing in comparison to zinc oxide eugenol dressing alone in the management of dry socket among females using oral contraceptives. The study assessed outcomes related to pain, quality of life, and socket volume.
Primary purpose: TREATMENT

Brief summary: does laser effect on alveolar osteitis recovery in oral contraceptive users ?

Detailed description: photo biomodulation therapy for alveolar osteitis recovery in oral contraceptive users

Eligibility criteria: * Inclusion Criteria:

Female patients aged 25-40 years. Currently using oral contraceptives for at least 3 months prior to participation.

Diagnosed with dry socket (alveolar osteitis) based on clinical criteria.

* Exclusion Criteria:

Presence of systemic diseases (e.g., diabetes, immunodeficiency disorders). Smoking or tobacco use. Allergies to zinc oxide or other study materials. Use of antibiotics or anti-inflammatory medications within the last 2 weeks. Pregnancy or breastfeeding.

Primary outcomes:
measure: pain intensity by VAS
timeFrame: 4 weeks
measure: Socket volume .
timeFrame: 4 weeks
Secondary outcomes:
measure: Quality of life assessed
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: physical therapy at Badr University in Cairo(BUC)
Study officials:
References:
Clinical trial NCT03846908: Postprandial Lipid Metabolism in Patients With Hypertriglyceridemia and Normo-lipidemic Controls: Medium Chain Fatty Acids (MCT) in Comparison to Long-chain, Saturated Fatty Acids (SFA) and Mono-unsaturated Fatty Acids (MUFA)
Official title: Postprandial Lipid Metabolism in Patients With Hypertriglyceridemia and Normo-lipidemic Controls: Medium Chain Fatty Acids (MCT) in Comparison to Long-chain, Saturated Fatty Acids (SFA) and Mono-unsaturated Fatty Acids (MUFA)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypertriglyceridemia
Lead sponsor: Ludwig-Maximilians - University of Munich
Sponsor class: OTHER
First posted: 2019-02-20
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Postprandial lipid metabolism will be evaluated in patients with hypertriglyceridemia and normo-lipidemic controls; different fats will be used (saturated fatty acids, mon-unsaturated fatty acids and medium chain fatty acids) for the oral fat challenge.


Eligibility criteria: Inclusion Criteria:

* hypertriglyceridemia (150 mg/dl-900 mg/dl)

Exclusion Criteria:

* Lipid lowering drugs or indication for Lipid lowering drugs
* LDL-cholesterol \> 190 mg/dl
* Diabetes mellitus

Primary outcomes:
measure: postprandial hypertriglyceridemia
timeFrame: 8 hours after fat meal
Secondary outcomes:
Other outcomes:
Locations:
city: Munich
country: Germany
facility: University Munich
Study officials:
References:
Clinical trial NCT03748108: Bolus Administration of Intravenous Lidocaine at the Time of Abdominal Hysterectomy
Official title: A Randomized Clinical Trial Estimating the Efficacy of Bolus Administration of Intravenous Lidocaine at the Time of Abdominal Hysterectomy to Decrease Postoperative Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Hysterectomy
Keywords: lidocaine
Postoperative Pain
hysterectomy
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2018-11-20
Enrollment: 120
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study will be a single-center, randomized double-blind, placebo-controlled, parallel group trial.
Primary purpose: PREVENTION

Brief summary: The objective of the study to evaluate whether a bolus administration of intravenous lidocaine decreases postoperative pain and represents an opioid-minimizing strategy after abdominal hysterectomy compared with placebo.

Detailed description: Total abdominal hysterectomy (TAH) is the most common gynecological operation worldwide. Some studies noticed about abused of opioids in postoperative care, led to a more adverse effect of opioids, slow recovery, prolong the length of hospitalized stay and consequently increase the unnecessary cost of treatment.

Guidelines have considered using preoperative analgesics for reducing post-operative opioids consumption, including lidocaine infusion. With its anti-inflammatory, anti-hyperalgesia and analgesic properties, intravenous perioperative lidocaine infusion (IVLI) has been used for optimal postoperative care in different surgeries and in various procedures involving hysterectomy.

Therefore, the aim of this study is to assess the efficacy of bolus administration of intravenous lidocaine at the time of abdominal hysterectomy to decrease postoperative pain and reducing morphine requirements, after TAH.

Eligibility criteria: Inclusion Criteria:

* Women ranging age between 35-60 years a who undergoing elective total abdominal hysterectomy

Exclusion Criteria:

* Participants had known sensitivity to lidocaine
* Participants had difficulty in intubation
* Participants were on chronic pain medication or already on long-term opioids
* Participants smokers
* Participants with disabilities who were unable to communicate pain levels
* refuse to consent

Primary outcomes:
measure: Visual analog score during movement
timeFrame: 30 minutes postoperative
Secondary outcomes:
measure: Visual analog score during rest
timeFrame: 24 hours post operative
measure: number of patients need Fentanyl consumption
timeFrame: 24 hours post operative
measure: number of days patients stay in hospital
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University
Study officials:
affiliation: Aswan University Hospital
name: hany f sallam, md
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00265408: Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection
Official title: Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Ischemic Stroke
Keywords: Cervicocephalic Arterial Dissection
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2005-12-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection.

Detailed description: 20 patients with cervicocephalic arterial dissection will be randomized to open-label aspirin or warfarin, rate of stroke and adverse events will be endpoints.

Eligibility criteria: Inclusion Criteria:

* Clinical and imaging diagnosis of cervicocephalic arterial dissection within 3 months.

Exclusion Criteria:

* Any contraindication to aspirin or warfarin.

Primary outcomes:
measure: Incidence of stroke by one year.
timeFrame: 1 year
Secondary outcomes:
measure: Recurrent dissection by one year.
timeFrame: 1 year
measure: Incidence of TIA by one year.
timeFrame: 1 year
measure: Incidence of major and minor bleeding episodes by one year.
timeFrame: 1 year
Other outcomes:
Locations:
city: San Diego
country: United States
facility: UCSD Medical Center
state: California
Study officials:
affiliation: UCSD Stroke Center
name: Matt B Jensen, MD
role: PRINCIPAL_INVESTIGATOR
References: